- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of November 26
The Center for Biosimilars® recaps the top news for the week of November 26, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 26.
Number 5: Two new biosimilar pegfilgrastim products were authorized in the European Union this week, Ziextenzo and Pelmeg.
Number 4: The United Kingdom’s National Health Service announced that it completed negotiations this week over using the best-value adalimumab product. Under the new plan, it will save 300 million pounds of its current 400 million pounds per year spending on adalimumab.
Number 3: A newly proposed rule from CMS would allow plans to make broader use of prior authorization and step therapy for drugs— including drugs in protected classes­– that are covered under Medicare Part D.
Number 2: The European Commission, in conjunction with the Organization for Economic Co-operation and Development, released its annual Health at a Glance report which highlights the need for and value of generic and biosimilar products in Europe.
Number 1: The FDA approved Celltrion and Teva’s rituximab biosimilar this week, to be sold as Truxima.
Finally, last week, our e-newsletter asked if you agree that anti-biosimilar campaigns in the United States foster negative perceptions of biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
